Thromboprophylaxis in patients with Covid-19

For two years, the entire world has been grappling with new challenge that is Covid-19 pandemic. In December 2019 in China’s largest province, Wuhan, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), was detected a patient severe respiratory failure. Shortly after, infections were all regions of world. So far, 265 million have confirmed around world, and 5.2 those infected died due to Covid-19. Infection SARS-CoV-2 associated an increased risk cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents basic form prophylaxis against complications individuals who are ill COVID-19. Controversy still exists regarding optimal dose LMWH depending on disease severity, this problem requires further randomised trials.